WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 525317
Description: JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.
MedKoo Cat#: 525317
Chemical Formula: C9H10N2O2S2
Exact Mass: 242.01837
Molecular Weight: 242.32
Elemental Analysis: C, 44.61; H, 4.16; N, 11.56; O, 13.21; S, 26.47
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JNJ-26990990; JNJ26990990; JNJ 26990990.
IUPAC/Chemical Name: Sulfamide, (benzo(b)thien-3-ylmethyl)-
InChi Key: AWSKBQNOSRREEY-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H10N2O2S2/c10-15(12,13)11-5-7-6-14-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H2,10,12,13)
SMILES Code: O=S(NCC1=CSC2=CC=CC=C21)(N)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 242.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Di Fiore A, De Simone G, Alterio V, Riccio V, Winum JY, Carta F, Supuran CT. The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. Org Biomol Chem. 2016 Jun 7;14(21):4853-8. doi: 10.1039/c6ob00803h. Epub 2016 May 6. PubMed PMID: 27151329.
2: Lin R, Weaner LE, Hoerr DC, Salter R, Gong Y. Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites. J Labelled Comp Radiopharm. 2013 Jan;56(1):22-6. doi: 10.1002/jlcr.3013. Epub 2013 Jan 10. PubMed PMID: 24285137.
3: Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, Malatynska E, White HS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Iannucci R, Leclercq L, Cuyckens F, Reitz AB, Maryanoff BE. Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. J Med Chem. 2009 Dec 10;52(23):7528-36. doi: 10.1021/jm801432r. PubMed PMID: 19388676.